← Back to Clinical Trials
Recruiting NCT07210164

NCT07210164 Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07210164
Status Recruiting
Phase
Sponsor Aristotle University Of Thessaloniki
Condition ERAS
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2025-12-01
Primary Completion 2029-12-30

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
OcoxinStructured self-guided exercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2025-12-01 with a primary completion date of 2029-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

ERAS (Enhanced Recovery After Surgery) protocols are step-by-step care plans that help patients recover faster after surgery. They focus on keeping the body's normal functions, lowering stress from surgery, and supporting a quicker recovery. In gynecologic cancer surgeries, ERAS has been shown to help patients do better, have fewer problems, and leave the hospital sooner. A prehabilitation program, in combination with ERAS protocols, aims to optimize patients' physical and psychological condition prior to surgery for gynecological cancers. Interventions may include tailored exercise, nutritional support, respiratory training, and psychological preparation. By enhancing baseline fitness and resilience, prehabilitation improves the body's ability to tolerate surgical stress, reduces complications, and facilitates a faster, smoother recovery within the ERAS framework.

Eligibility Criteria

Inclusion Criteria: * Type of gynecological malignancy: endometrial cancer, ovarian cancer, cervical cancer, treated with laparotomy after the decision of the gynecological-oncology unit (positive opinion of the Multidisciplinary Tumor Board - MDT) * Patient age: 18 to 85 years * General condition of the patient: ASA score I-III * Consent to implement the accelerated recovery protocol - Enhanced recovery after surgery (ERAS) * Sufficient understanding of the Greek language * Provision of signed, after thorough information, consent to participate in the study Exclusion Criteria: * Women with performance status: ECOG \>2 and ASA score \>III * Women who have not been informed and have given written consent

Contact & Investigator

Central Contact

Dimitrios Tsolakidis C. MD, PhD, Professor OB&GYN

✉ dtgyn@auth.gr

📞 +30 2313 32 3380

Principal Investigator

Dimitrios C. Tsolakidis, MD, PhD

STUDY CHAIR

Professor of Obstetrics - Gynaecology, Aristotel University of Thessaloniki

Frequently Asked Questions

Who can join the NCT07210164 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 85 Years, studying ERAS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07210164 currently recruiting?

Yes, NCT07210164 is actively recruiting participants. Contact the research team at dtgyn@auth.gr for enrollment information.

Where is the NCT07210164 trial being conducted?

This trial is being conducted at Thessaloniki, Greece.

Who is sponsoring the NCT07210164 clinical trial?

NCT07210164 is sponsored by Aristotle University Of Thessaloniki. The principal investigator is Dimitrios C. Tsolakidis, MD, PhD at Professor of Obstetrics - Gynaecology, Aristotel University of Thessaloniki. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology